查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949599

C反應蛋白檢測市場－全球產業規模、佔有率、趨勢、機會及預測（依檢測類型、檢測範圍、疾病領域、最終用途產業、地區及競爭格局分類，2021-2031年）

C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Assay Type, By Detection Range, By Disease Area, By End-Use Industry, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 C 反應蛋白檢測市場預計將從 2025 年的 19.5 億美元成長到 2031 年的 22.1 億美元，複合年成長率為 2.11%。

這種診斷方法可定量檢測血液樣本中的C反應蛋白，C反應蛋白是全身性發炎、細菌感染疾病和心血管風險的重要生物標記。推動市場成長的主要因素是慢性心血管疾病和發炎性疾病發生率的上升，這些疾病需要病患監測和風險評估。例如，美國心臟協會（AHA）報告稱，到2025年，全球心血管疾病患病人數將達到約6.12億，凸顯了發炎標記的重要性。此外，全球人口老化以及向分散式就地檢驗解決方案的顯著轉變也是推動市場成長的因素。

市場概覽
預測期 2027-2031
市場規模：2025年 19.5億美元
市場規模：2031年 22.1億美元
複合年成長率：2026-2031年 2.11%
成長最快的細分市場 檢測法
最大的市場 北美洲

然而，阻礙市場發展的主要障礙是嚴格的監管環境和各地不同的報銷政策。這些行政和經濟障礙往往會延緩新型檢測平台的商業性核准，並限制醫療機構使用高靈敏度診斷工具的經濟可行性。因此，這些障礙阻礙了先進診斷解決方案的廣泛應用和市場滲透。

市場促進因素

慢性病和發炎性疾病負擔的日益加重，是推動全球C反應蛋白檢測市場發展的主要動力。全身性發炎是心血管疾病、糖尿病和自體免疫疾病的核心組成部分，因此，臨床上對精準生物標記追蹤疾病進展的需求日益成長。鑑於非傳染性疾病的廣泛影響，醫療專業人員擴大利用C反應蛋白檢測進行發炎的早期發現和有效治療。根據世界衛生組織（世衛組織）2024年4月發布的概況介紹，非傳染性疾病每年導致4,100萬人死亡，佔全球死亡總數的74%。這項數據凸顯了製定嚴格診斷通訊協定的必要性，以及醫院和門診對C反應蛋白檢測的迫切需求。

同時，就地檢驗平台的日益普及也正在影響市場格局。這些平台分散了診斷流程，並能加快臨床決策速度。這些攜帶式設備無需前往傳統檢查室即可進行即時蛋白質水平分析，有助於區分細菌感染和病毒感染，並最大限度地減少不恰當的抗生素使用。主要製造商正在擴展其產能，以適應醫療服務分散化的趨勢。例如，雅培公司在2024年10月發布的財務報告中顯示，全球整體診斷業務銷售額達24億美元，凸顯了市場對便利診斷工具的持續需求。此外，聯合國發布的2024年人口趨勢報告顯示，全球65歲及以上人口將顯著成長，將增加易患發炎性疾病的患者群體，並提高對定期健康監測的需求。

市場挑戰

全球C反應蛋白檢測市場的成長受到嚴格法規環境和不一致的報銷策略的顯著限制。製造商必須應對複雜且不斷變化的合規標準，這延長了核准流程並增加了研發成本。這種監管壓力迫使企業將大量資金從高靈敏度檢測的研發中轉移，減緩了新型先進診斷技術的推出。因此，核准流程的不確定性阻礙了新產品在關鍵市場的上市，並限制了醫療服務提供者可用於有效病患監測的診斷選擇。

除了監管障礙外，不明確的報銷機制也帶來了財務風險，阻礙了這些檢測技術的廣泛應用。臨床檢查室往往在沒有明確支付保障的情況下，不願意投資現代診斷平台，這直接阻礙了市場滲透。 MedTech Europe發布的2025年數​​據顯示，體外診斷醫療設備法規（IVDR）下的認證成本較先前的標準飆升了高達100%。這導致選擇歐盟作為主要上市區域的主要製造商數量下降了40%。這表明，行政和經濟壁壘正在切實限制市場擴張的潛力。

市場趨勢

隨著醫療系統將診斷演算法納入國家抗擊抗菌藥物抗藥性策略，C反應蛋白（CRP）檢測在抗菌藥物管理計畫中的應用正從根本上改變市場需求。為了確保與全球抗菌藥物管理目標保持一致，越來越多的醫療機構通訊協定要求在應用抗生素前進行CRP篩檢，這使得該檢測從標準診斷工具提升為監管合規的關鍵組成部分。這種轉變推動了快速檢測平台的採購，使其成為檢驗公共衛生合規性的關鍵基礎設施，尤其是在呼吸道感染疾病治療方法選擇方面。正如雅培公司2024年1月發表的一篇報導所述，就地檢驗結合溝通訓練已被證明可將抗生素處方量減少60%以上。

同時，高敏C反應蛋白（hs-CRP）在心血管風險分層中的廣泛應用，正將這項檢測的範圍從急性發炎監測擴展到長期預防性心臟病學。臨床醫師越來越重視hs-CRP在檢測無症狀個體殘餘發炎風險的應用，從而能夠採取早期療育策略，補充傳統的血脂管理。隨著越來越多的臨床證據支持生物標記能夠預測未來不利事件，這一趨勢正在加速發展，促使醫療保健機構將這些檢測納入常規篩檢。例如，2024年8月在歐洲心臟病學會（ESC）大會上發表的一項研究表明，與C反應蛋白水平最低的女性相比，C反應蛋白水平高的女性患心臟病的風險增加了70%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球C反應蛋白檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依檢測類型（免疫比濁法、酵素連結免疫吸附試驗、化學冷光免疫檢測、其他）
    • 依檢測範圍（高靈敏度CRP、常規CRP、cCRP）
    • 依疾病領域（心血管疾病、癌症、類風濕性關節炎、發炎性腸道疾病、子宮內膜異位症、全身性紅斑性狼瘡、其他）
    • 按最終用戶行業（醫院/診所、檢查室、療養院、居家醫療、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美C反應蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲C反應蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區C反應蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲C反應蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲C反應蛋白檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球C反應蛋白檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corp
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Abbott Laboratories Inc.
  • Merck KGaAA
  • Zoetis Inc.
  • Ortho Clinical Diagnostics
  • Getein Biotech, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17192

The Global C-reactive Protein Testing Market is projected to expand from USD 1.95 Billion in 2025 to USD 2.21 Billion by 2031, reflecting a CAGR of 2.11%. This diagnostic method, which quantifies C-reactive protein in blood samples, serves as a vital biomarker for systemic inflammation, bacterial infections, and cardiovascular risks. Growth is largely fueled by the rising incidence of chronic cardiovascular and inflammatory conditions that require ongoing patient monitoring and risk assessment. For instance, the American Heart Association reported that the global prevalence of cardiovascular disease reached approximately 612 million cases in 2025, highlighting the critical need for inflammatory markers. Additionally, the market is bolstered by an aging global population and a noticeable transition toward decentralized point-of-care testing solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.95 Billion
Market Size 2031USD 2.21 Billion
CAGR 2026-20312.11%
Fastest Growing SegmentImmunoturbidimetric Assays
Largest MarketNorth America

However, a major obstacle hindering market progress is the strict regulatory landscape combined with variable reimbursement policies across different regions. These administrative and economic hurdles often postpone the commercial authorization of novel testing platforms and restrict the financial viability of high-sensitivity diagnostic tools for healthcare providers. Consequently, these barriers limit the broader adoption and market penetration of advanced diagnostic solutions.

Market Driver

The escalating burden of chronic and inflammatory diseases acts as a primary engine for the Global C-reactive Protein Testing Market's development. Because systemic inflammation is a core component of cardiovascular diseases, diabetes, and autoimmune conditions, the clinical imperative for precise biomarkers to track disease progression has grown stronger. Medical professionals are increasingly utilizing C-reactive protein assays for early inflammation detection and effective therapy management, especially considering the vast impact of noncommunicable diseases. According to the World Health Organization's April 2024 fact sheet, noncommunicable diseases are responsible for 41 million deaths annually, accounting for 74% of global mortality, a statistic that underscores the necessity for rigorous diagnostic protocols and high demand for testing in both hospital and outpatient environments.

Simultaneously, the market is being shaped by the growing integration of point-of-care testing platforms, which decentralize diagnostic processes and facilitate swift clinical decision-making. These portable devices enable immediate protein level analysis outside of traditional laboratories, aiding in the differentiation between bacterial and viral infections and helping to minimize inappropriate antibiotic use. Major manufacturers are expanding their capabilities to address this shift towards decentralized care; for example, Abbott reported worldwide Diagnostics sales of USD 2.4 billion in their October 2024 results, highlighting the persistent demand for accessible diagnostic tools. Furthermore, demographic trends identified by the United Nations in 2024 indicate a significant rise in the global population aged 65 and older, increasing the patient base susceptible to inflammatory conditions and driving the need for regular health monitoring.

Market Challenge

Growth in the Global C-reactive Protein Testing Market is heavily constrained by a rigorous regulatory environment and inconsistent reimbursement strategies. Manufacturers must navigate complex and shifting compliance standards that prolong approval processes and escalate development expenses. This regulatory pressure forces companies to divert crucial capital away from the research and development of high-sensitivity assays, thereby delaying the commercial launch of advanced diagnostic innovations. As a result, the uncertainty surrounding approval pathways often deters companies from introducing new products in major markets, ultimately limiting the diagnostic options available to healthcare providers for effective patient monitoring.

In addition to regulatory hurdles, ambiguous reimbursement frameworks introduce financial risks that inhibit the uptake of these tests. Clinical laboratories are frequently hesitant to invest in modern diagnostic platforms lacking clear payment assurances, a factor that directly impedes market penetration. Data from MedTech Europe in 2025 highlighted the severity of this issue, revealing that certification costs under the In Vitro Diagnostic Regulation surged by up to 100% compared to earlier standards, prompting a 40% reduction in large manufacturers choosing the European Union as their primary launch region. This demonstrates how administrative and economic impediments actively suppress the market's potential for broader expansion.

Market Trends

The utilization of CRP testing within Antimicrobial Stewardship Programs is fundamentally transforming market demand as healthcare systems incorporate diagnostic algorithms into national strategies against drug resistance. Institutional protocols increasingly require CRP screening before antibiotic administration to ensure alignment with global stewardship objectives, thereby elevating the assay from a standard diagnostic tool to a vital element of regulatory compliance. This shift drives the acquisition of rapid testing platforms as critical infrastructure for public health adherence, particularly for validating treatment choices in respiratory infections. As noted in an Abbott article from January 2024, utilizing C-reactive protein point-of-care testing alongside communication training has been demonstrated to decrease antibiotic prescribing by over 60%.

Concurrently, the widespread application of High-Sensitivity CRP (hs-CRP) for cardiovascular risk stratification is broadening the test's scope from monitoring acute inflammation to long-term preventative cardiology. Clinicians are placing greater emphasis on hs-CRP to detect residual inflammatory risks in asymptomatic individuals, enabling early intervention strategies that complement traditional lipid management. This trend is gaining momentum as fresh clinical evidence confirms the biomarker's ability to predict future adverse events over long periods, encouraging providers to add these assays to routine screenings. For instance, research presented at the European Society of Cardiology Congress in August 2024 indicated that women with elevated C-reactive protein levels faced a 70% higher risk of heart disease compared to those with the lowest levels.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corp
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Abbott Laboratories Inc.
  • Merck KGaAA
  • Zoetis Inc.
  • Ortho Clinical Diagnostics
  • Getein Biotech, Inc.

Report Scope

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

C-reactive Protein Testing Market, By Assay Type

  • Immunoturbidimetric Assay
  • ELISA
  • Chemiluminescence Immunoassay
  • Others

C-reactive Protein Testing Market, By Detection Range

  • hs-CRP
  • Conventional CRP
  • cCRP

C-reactive Protein Testing Market, By Disease Area

  • Cardiovascular Diseases
  • Cancer
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Endometriosis
  • Lupus
  • Others

C-reactive Protein Testing Market, By End-Use Industry

  • Hospitals & Clinics
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Homecare
  • Others

C-reactive Protein Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

Global C-reactive Protein Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global C-reactive Protein Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others)
    • 5.2.2. By Detection Range (hs-CRP, Conventional CRP, cCRP)
    • 5.2.3. By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others)
    • 5.2.4. By End-Use Industry (Hospitals & Clinics, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America C-reactive Protein Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Assay Type
    • 6.2.2. By Detection Range
    • 6.2.3. By Disease Area
    • 6.2.4. By End-Use Industry
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States C-reactive Protein Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Assay Type
        • 6.3.1.2.2. By Detection Range
        • 6.3.1.2.3. By Disease Area
        • 6.3.1.2.4. By End-Use Industry
    • 6.3.2. Canada C-reactive Protein Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Assay Type
        • 6.3.2.2.2. By Detection Range
        • 6.3.2.2.3. By Disease Area
        • 6.3.2.2.4. By End-Use Industry
    • 6.3.3. Mexico C-reactive Protein Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Assay Type
        • 6.3.3.2.2. By Detection Range
        • 6.3.3.2.3. By Disease Area
        • 6.3.3.2.4. By End-Use Industry

7. Europe C-reactive Protein Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Assay Type
    • 7.2.2. By Detection Range
    • 7.2.3. By Disease Area
    • 7.2.4. By End-Use Industry
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany C-reactive Protein Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Assay Type
        • 7.3.1.2.2. By Detection Range
        • 7.3.1.2.3. By Disease Area
        • 7.3.1.2.4. By End-Use Industry
    • 7.3.2. France C-reactive Protein Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Assay Type
        • 7.3.2.2.2. By Detection Range
        • 7.3.2.2.3. By Disease Area
        • 7.3.2.2.4. By End-Use Industry
    • 7.3.3. United Kingdom C-reactive Protein Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Assay Type
        • 7.3.3.2.2. By Detection Range
        • 7.3.3.2.3. By Disease Area
        • 7.3.3.2.4. By End-Use Industry
    • 7.3.4. Italy C-reactive Protein Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Assay Type
        • 7.3.4.2.2. By Detection Range
        • 7.3.4.2.3. By Disease Area
        • 7.3.4.2.4. By End-Use Industry
    • 7.3.5. Spain C-reactive Protein Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Assay Type
        • 7.3.5.2.2. By Detection Range
        • 7.3.5.2.3. By Disease Area
        • 7.3.5.2.4. By End-Use Industry

8. Asia Pacific C-reactive Protein Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Assay Type
    • 8.2.2. By Detection Range
    • 8.2.3. By Disease Area
    • 8.2.4. By End-Use Industry
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China C-reactive Protein Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Assay Type
        • 8.3.1.2.2. By Detection Range
        • 8.3.1.2.3. By Disease Area
        • 8.3.1.2.4. By End-Use Industry
    • 8.3.2. India C-reactive Protein Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Assay Type
        • 8.3.2.2.2. By Detection Range
        • 8.3.2.2.3. By Disease Area
        • 8.3.2.2.4. By End-Use Industry
    • 8.3.3. Japan C-reactive Protein Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Assay Type
        • 8.3.3.2.2. By Detection Range
        • 8.3.3.2.3. By Disease Area
        • 8.3.3.2.4. By End-Use Industry
    • 8.3.4. South Korea C-reactive Protein Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Assay Type
        • 8.3.4.2.2. By Detection Range
        • 8.3.4.2.3. By Disease Area
        • 8.3.4.2.4. By End-Use Industry
    • 8.3.5. Australia C-reactive Protein Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Assay Type
        • 8.3.5.2.2. By Detection Range
        • 8.3.5.2.3. By Disease Area
        • 8.3.5.2.4. By End-Use Industry

9. Middle East & Africa C-reactive Protein Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Assay Type
    • 9.2.2. By Detection Range
    • 9.2.3. By Disease Area
    • 9.2.4. By End-Use Industry
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia C-reactive Protein Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Assay Type
        • 9.3.1.2.2. By Detection Range
        • 9.3.1.2.3. By Disease Area
        • 9.3.1.2.4. By End-Use Industry
    • 9.3.2. UAE C-reactive Protein Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Assay Type
        • 9.3.2.2.2. By Detection Range
        • 9.3.2.2.3. By Disease Area
        • 9.3.2.2.4. By End-Use Industry
    • 9.3.3. South Africa C-reactive Protein Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Assay Type
        • 9.3.3.2.2. By Detection Range
        • 9.3.3.2.3. By Disease Area
        • 9.3.3.2.4. By End-Use Industry

10. South America C-reactive Protein Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Assay Type
    • 10.2.2. By Detection Range
    • 10.2.3. By Disease Area
    • 10.2.4. By End-Use Industry
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil C-reactive Protein Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Assay Type
        • 10.3.1.2.2. By Detection Range
        • 10.3.1.2.3. By Disease Area
        • 10.3.1.2.4. By End-Use Industry
    • 10.3.2. Colombia C-reactive Protein Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Assay Type
        • 10.3.2.2.2. By Detection Range
        • 10.3.2.2.3. By Disease Area
        • 10.3.2.2.4. By End-Use Industry
    • 10.3.3. Argentina C-reactive Protein Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Assay Type
        • 10.3.3.2.2. By Detection Range
        • 10.3.3.2.3. By Disease Area
        • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global C-reactive Protein Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Danaher Corp
  • 15.4. Quest Diagnostics
  • 15.5. Siemens Healthineers AG
  • 15.6. Abbott Laboratories Inc.
  • 15.7. Merck KGaAA
  • 15.8. Zoetis Inc.
  • 15.9. Ortho Clinical Diagnostics
  • 15.10. Getein Biotech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer